(Total Views: 326)
Posted On: 09/24/2018 8:47:52 AM
Post# of 72446
Where did I say that IV drug works better? As far as I can tell Brilacidin has slight efficacy edge over GC4419 based on hazard ratio for SOM incidences, HR = 0.93 Brilacidin over GC4419. That number is based on Kaplan Meier estimates for reported incidences in both trials. And, because KM estimates for incidences in placebo arms turned out to be virtually identical with HR exactly 1.0 that efficacy edge has more meaning than one would otherwise expect from this kind of ad hoc comparison.
As to rest of our 'discussion' I refer you to a recent review by Bryan Oronsky et. al. Oronsky has his own radioprotective compound to push hence the review is limited to those to plus miserable palifermin as reference. But they do good work of explaining the mechanism of oral mucositis. Figure 3 in the article is adaptation of Dr. Sonis' model I mentioned before.
You find the article here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918142/
Good luck for all IPIX shareholders.
As to rest of our 'discussion' I refer you to a recent review by Bryan Oronsky et. al. Oronsky has his own radioprotective compound to push hence the review is limited to those to plus miserable palifermin as reference. But they do good work of explaining the mechanism of oral mucositis. Figure 3 in the article is adaptation of Dr. Sonis' model I mentioned before.
You find the article here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918142/
Good luck for all IPIX shareholders.
(1)
(0)
